Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have successfully completed the previous double-blind study AGAL-008-00 (NCT00074984)
Patients must provide written informed consent prior to study participation
Female patients of childbearing potential must have a negative pregnancy test prior to each dosing and all female patients must use a medically accepted form of contraception throughout the study
You may not be if
The patient was unable to complete AGAL-008-00 (NCT00074984)
The patient has undergone kidney transplantation or is currently on dialysis
The patient has diabetes mellitus or presence of confounding renal disease
The patient has a clinically significant organic disease or an unstable condition that precludes participation
The patient is unwilling to comply with the protocol requirements
Clareo Health | A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
